Clostridium Difficile Infection – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of clostridium difficile infection (CDI) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of CDI for each country, as well as annualized case counts projected to the national population.
In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.
Clarivate Epidemiology’s CDI forecast will answer the following questions:
- Of all people diagnosed with CDI, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CDI over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 48 CDI patient populations, including the following:
- Diagnosed hospital treated events of C. difficile infection.
- Diagnosed hospital treated events of recurrent C. difficile infection.
- Diagnosed hospital treated events of severe C. difficile infection.
- Diagnosed hospital treated events of healthcare-associated C. difficile infection.
- Diagnosed hospital treated events of hospital-onset C. difficile infection.
- Diagnosed hospital treated events of community-onset, healthcare-associated C. difficile infection.
- Diagnosed hospital treated events of nursing home-onset C. difficile infection.
- Diagnosed hospital treated events of community-associated C. difficile infection.
- Diagnosed hospital treated events of C. difficile infection with comorbidities.
- Diagnosed hospital treated events of drug-treated C. difficile infection.
Note: Coverage may vary by country.
Table of contents
- Clostridium Difficile Infection - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Hospitalization Rate of Clostridium Difficile Infection per 1,000 People of All Ages in 2021 and 2031
- Hospitalization rate of Clostridium Difficile Infection per 1,000 People of All Ages in 2021 and 2031
- Relative Sizes of the Factors Contributing to the Trend in Hospitalization of Clostridium Difficile Infection Over the Next 10 Years
- Relative Sizes of the Factors Contributing to the Trend in Hospitalization of Clostridium Difficile Infection Over the Next 10 Years
- Analysis of Hospitalization of Clostridium Difficile Infection in the Countries Under Study, by Stage: 2021
- Analysis of Hospitalization of Clostridium Difficile Infection in the Countries Under Study, by Stage: 2021
- Epidemiology Data
- Methods
- Hospitalized Clostridium Difficile Infection
- Hospitalized Clostridium Difficile Infection by Recurrence
- Hospitalized Clostridium Difficile Infection by Severity
- Healthcare-Associated Hospitalized Clostridium Difficile Infection
- Hospital-Onset Hospitalized Clostridium Difficile Infection
- Community-Onset Healthcare-Associated Hospitalized Clostridium Difficile Infection
- Nursing Home-Onset Hospitalized Clostridium Difficile Infection
- Community-Associated Hospitalized Clostridium Difficile Infection
- Hospitalized Clostridium Difficile Infections with Comorbidities
- Hospitalized Drug-Treated Clostridium Difficile Infection
- Reference Materials
- Introduction
Yueyao (Alex) Li, M.D., Ph.D., M.S.P.H., is an associate epidemiologist at Clarivate. Previously, she was a postdoctoral researcher at Brown University, where she worked on projects relating to skin cancer and chronic skin conditions. Dr. Li holds a medical degree specializing in general surgery from China Medical University. She also holds a Ph.D. in epidemiology from Indiana University and a master’s degree in public health from the University of South Carolina.
Sunali D. Goonesekera, S.M., Senior Manager, Epidemiology. Prior to joining Clarivate, Ms. Goonesekera conducted epidemiological research on racial/ethnic disparities in metabolic diseases at the New England Research Institute and lead-authored two manuscripts. She has contributed to multiple publications in peer-reviewed journals in epidemiology and the biological sciences. She holds a master’s degree in epidemiology from the Harvard School of Public Health and a B.A. in biology (Honors) from Dartmouth College.